Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses
businesswire.com
⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in